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Abstract
Hepatitis  C  virus  is  associated  with  several  immune-mediated  phenomena,  presented
usually as  extra-hepatic  hepatitis  C  manifestations.  A  predisposition  to  autoimmunity  asso-
ciated with  the  presence  of  baseline  autoantibodies  has  been  demonstrated  in  interferon
mediated  autoimmune  diseases.  We  report  a  male  patient,  34  years  old,  with  genotype  1,
chronic hepatitis  C  (hepatitis  C  viremia  1.432.463  UI/mL)  and  family  history  of  psoriasis.  He
had high  levels  of  transaminases  and  immunology  showed  positive  antinuclear  antibodies
(1/320) and  anti-smooth-muscle  antibodies,  with  elevated  immunoglobulin  G  (1740  mg/dL).
Liver biopsy  revealed  a  F1/2  Metavir  score,  histologic  activity  index  of  3  and  mild  piecemeal
necrosis. Antiviral  treatment  was  started  with  peg-interferon  2a  180  mcg  plus  ribavirin
1200 mg,  and  the  patient  had  rapid  virologic  response,  normalization  of  transaminases,  nega-
tivation of  antinuclear  antibodies  positivity  and  decrease  of  immunoglobulin  levels.  However,
at week  22,  he  developed  psoriatic-like  eczema  and  arthritis  with  functional  limitation.
Due to  suspicion  of  latent  psoriatic  arthritis  not  previously  diagnosed,  he  was  started  on
methotrexate  10  mg/weekly  with  improvement  of  psoriatic  plaques,  arthritis  and  functional
limitation.  Patient  achieved  sustained  virologic  response,  with  normal  transaminases  and  no
signiﬁcant  changes  in  immunology.  Post-treatment  median  hepatic  elastography  was  3.6  kPa.
Autoimmunity  in  hepatitis  C  infection  is  not  limited  to  surrogate  autoantibody  seropositivity,
but may  embrace  the  full  spectrum  of  autoimmune  disorders.
© 2014  Sociedade  Portuguesa  de  Gastrenterologia.  Published  by  Elsevier  España,  S.L.U.  All  rights
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Signiﬁcado  Clínico  dos  Auto-anticorpos  nos  Doentes  com  Hepatite  C  Tratados  com
Interferão  Peguilado
Resumo
O  vírus  da  hepatite  C  associa-se  a  diversos  fenómenos  de  auto-imunidade,
apresentando-se  geralmente  como  manifestac¸ões  extra-hepáticas  da  hepatite  C.  Uma
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predisposic¸ão  para  auto-imunidade  associada  à  presenc¸a  de  auto-anticorpos  foi  demon-
strada em  doenc¸as  auto-imunes  mediadas  pelo  Interferão.  Descrevemos  um  doente  do  sexo
masculino,  34  anos,  com  hepatite  C  crónica,  genótipo  1  (viremia  1.432.463  UI/mL)  e  história
familiar  de  psoríase.  Apresentava  transaminases  elevadas  e  imunologia  positiva  para  anticorpos
antinucleares  (1/320)  e  anti-musculo  liso,  com  imunoglobulina  G  elevada  (1740  mg/dL).  A
biópsia hepática  revelou  um  score  Metavir  F1/2,  índice  de  actividade  histológica  de  3  e  necrose
piecemeal  ligeira.  Foi  iniciado  tratamento  antivírico  com  Interferão  peguilado  -2a  180  mcg
e Ribavirina  1200  mg,  com  resposta  virológica  rápida  e  normalizac¸ão  das  transaminases,
com negativac¸ão  dos  anticorpos  antinucleares  e  diminuic¸ão  dos  níveis  de  imunoglobulina  G.
Contudo, à  semana  22,  apresentou  eczema  do  tipo  psoriático  e  artrite  com  limitac¸ão  funcional.
Devido  à  suspeita  de  artrite  psoriática  latente  não  diagnosticada  previamente,  iniciou  trata-
mento com  Metotrexato  10  mg/semana  com  melhoria  das  placas  de  psoríase,  artrite  e  limitac¸ão
funcional.  O  doente  alcanc¸ou  resposta  virológica  sustentada,  com  transaminases  normais,
sem alterac¸ões  signiﬁcativas  da  imunologia.  A  elastograﬁa  hepática  mediana  pós-tratamento
foi de  3.6  kPa.  A  auto-imunidade  na  Hepatite  C  não  está  limitada  à  seropositividade  dos
auto-anticorpos,  podendo  abranger  todo  o  espectro  de  doenc¸as  auto-imunes.
© 2014  Sociedade  Portuguesa  de  Gastrenterologia.  Publicado  por  Elsevier  España,  S.L.U.  Todos
os direitos  reservados.
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biopsy  was  performed  for  differential  diagnosis  with  AIH.1. Introduction
Approximately  3%  of  the  world  population  is  chronically
infected  with  hepatitis  C  virus  (HCV).1 It  is  associated
with  several  immune-mediated  phenomena;  the  associa-
tion  between  serological  ﬁndings  suggestive  of  autoimmune
disease  and  HCV  is  well  known.  Antinuclear  antibodies
(ANA),  smooth-muscle  antibodies  (ASMA)  and  liver-kidney
microssome  1  (LKM1)  are  detected  in  25--30%  of  HCV
patients.2 The  mechanism  responsible  for  seropositivity  for
these  autoantibodies  is  not  completely  understood.  Molec-
ular  mimicry  of  viral  antigens  by  self-antigens,  chronic
stimulation  of  B  cells,  and  a  bystander  effect  are  some
proposed  mechanisms  for  the  development  of  autoimmune
phenomena  in  hepatitis  C.3
Patients  with  features  of  both  autoimmune  hepatitis
(AIH)  and  HCV  should  be  carefully  evaluated,  because
immunosuppressive  treatment  may  have  deleterious  effects
on  chronic  hepatitis  C  (CHC).  Conventional  therapy  of  HCV
consists  of  pegylated  interferon- (IFN-) combined  with
ribavirin  (RBV)  and  possibly  a  direct  acting  antiviral  (DAA)
agent  depending  on  genotype.4 IFN- has  been  reported  to
cause  drug-induced  AIH,5 however,  it  is  unclear  whether
it  unmasks,  induces  or  simply  causes  liver  injury  with
autoimmune  features.  HCV  alone  can  trigger  autoimmune
processes;  in  addition,  IFN- exerts  various  immunomodu-
latory  effects  that  may  further  facilitate  this  autoimmune
phenomenon.6 Diagnosing  AIH  in  patients  with  HCV  is  dif-
ﬁcult  on  the  basis  of  scoring  systems  because  several
serological  and  histological  ﬁndings,  which  are  incorporated
in  the  diagnostic  criteria,  can  also  be  observed  in  HCV.7 In
HCV  patients  with  AIH  features,  a  deﬁnitive  diagnosis  of  AIH
should  be  made  based  on  a  combination  of  autoantibody
proﬁles,  histological  ﬁndings,  and  therapy  response  and  out-
come.
An  association  between  HCV  and  psoriasis  has  previ-
ously  been  reported  and  a  recent  epidemiological  survey
conﬁrmed  a  higher  prevalence  of  HCV  infection  in  pso-
riatic  patients.  Psoriasis  induction  by  IFN- is  a  rare
complication  of  HCV  treatment,  ﬁrst  noted  in  1993.8
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aince  then,  there  have  been  41  cases  in  the  worldwide
iterature.
A  predisposition  to  autoimmunity  associated  with  the
resence  of  baseline  autoantibodies  has  been  demonstrated
n  IFN-mediated  autoimmune  diseases9 and  immunological
lterations  associated  with  HCV  may  constitute  a  predis-
osing  factor  in  the  onset  of  the  disease  in  IFN- treated
atients.10 Besides  that,  there  is  still  a  question  whether
CV  itself  can  be  one  of  the  inducing  factors  for  psoriasis.11
his  case  report  tries  to  explore  the  difﬁculties  in  the  dif-
erential  diagnosis  between  HCV  and  AIH,  as  well  as  the
linical  signiﬁcance  of  autoantibodies  in  the  development
f  autoimmune  manifestations,  like  psoriasis.
.  Case report
 male  patient,  34  year-old,  was  referred  to  the  Hepatol-
gy  outpatient  clinic  due  to  positive  serology  against  HCV
anti-HCV).  He  had  a  past  medical  history  of  intravenous
rug  addiction  between  1994  and  1998,  pulmonary  tuber-
ulosis  (treated)  in  1997,  and  alcohol  consumption  (less
han  20  g/day).  The  patient  was  asymptomatic  and  there
as  a  family  history  (grandfather)  of  psoriasis.  Labora-
ory  analysis  showed  increased  aspartate  aminotransferase
AST)  5  times  upper  limit  of  normal  (ULN)  and  alanine
minotransferase  (ALT)  10  times  ULN.  HCV-RNA  detected
y  polymerase  chain  reaction  (PCR)  was  1.432.463  UI/mL.
CV  genotype  was  1,  with  undetermined  subtype.  Immunol-
gy  showed  positive  ANA  (1/320)  and  ASMA,  with  elevated
mmunoglobulin  G  (IgG)  (1.2  times  ULN).  Anti-mitochondrial
ntibody,  anti-liver  kidney  microsomal  antibody  and  anti-
eutrophil  cytoplasmic  antibody  were  negative.  Tests  for
ron,  copper  metabolic  disorders,  alpha1  antitrypsin  and
omplement  were  normal.  Thyroid  function  tests  were  also
ormal.  The  abdominal  ultrasound  was  normal.  A  liverrabecular  architecture  was  preserved  with  mild  to  mod-
rate  portal  ﬁbrosis  with  focal  ﬁbrous  septa.  There  was
ortal  inﬂammatory  inﬁltrate,  predominantly  mononucle-
te  with  lymphoid  aggregates,  mild  piecemeal  necrosis  and
26  E.  Rodrigues-Pinto  et  al.
Figure  1  Liver  histology  showed  portal  inﬂammatory  inﬁl-
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Figure  3  Evolution  of  aspartate  aminotransferases  (AST)  and
alanine  aminotransferases  (ALT)  during  48  weeks  of  hepatitis
C treatment  with  peg-interferon  plus  ribavirin;  methotrexate
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orate, predominantly  mononucleate  with  lymphoid  aggregates,
ild piecemeal  necrosis  and  moderate  intra-lobular  necro-
nﬂammatory  activity.
oderate  intra-lobular  necro-inﬂammatory  activity  with  no
ther  signiﬁcant  changes  (Fig.  1).  AIH  score  without  treat-
ent  was  3  (probable  if  >  or  =  10)  and  simpliﬁed  score  was
 (probable  if  >  or  =  6).  Treatment  was  started  with  peg-
FN  2a  180  mcg  plus  RBV  1200  mg,  under  close  monitoring
f  liver  biochemistry  during  the  initial  weeks.  The  patient
chieved  a  fast  normalization  of  transaminases,  rapid  viro-
ogic  response  (RVR),  negativation  of  ANA  positivity  and
ecrease  of  IgG  levels.  At  week  22,  he  sought  his  clini-
ian  due  to  a  psoriatic-like  eczema  and  arthritis  (Fig.  2)
ith  functional  limitation.  Due  to  suspicion  of  latent  pso-
iatic  arthritis  not  previously  diagnosed,  the  patient  was
valuated  by  Rheumatology  and  started  methotrexate  (MTX)
igure  2  Hands  of  the  patient  with  psoriatic-like  eczema  and
rthritis.
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gas started  at  week  22,  with  dose  intensiﬁcation  at  week  28;
t week  30,  methotrexate  dose  was  decreased  to  the  initial
cheme.
0  mg/weekly  plus  calcipotriol  hydrate  and  bethametasone
ipropionate  with  dose  reduction  of  peg-IFN  to  135  mcg.
t  week  28,  patient  referred  partial  improvement  of  pso-
iatic  plaques,  arthritis  and  functional  limitation,  with
ose  intensiﬁcation  of  MTX  to  15  mg/weekly  and  complete
mprovement  of  symptomatology.  At  week  30,  there  was
n  increase  of  transaminases  to  2  times  ULN.  As  HCV
iremia  remained  negative,  and  there  was  no  evidence
f  immunological  ﬂare,  MTX  dose  was  decreased  to  the
nitial  scheme,  with  normalization  of  transaminases,  and
he  patient  managed  to  complete  48  weeks  of  antiviral
herapy.  The  patient  achieved  sustained  virologic  response
SVR),  with  no  signiﬁcant  changes  in  immunology  and  nor-
al  transaminases  (Fig.  3).  Post-treatment  median  hepatic
lastography  ﬁbroscan  was  3.6  kPa.  The  patient  is  asymp-
omatic  without  relapse  of  psoriasis  even  after  suspension
f  MTX  and  topic  therapy.
. Discussion
CV  infection  is  one  of  the  main  causes  of  chronic  liver
isease  worldwide.  Patients  found  to  be  anti-HCV  positive,
hould  have  their  HCV  genotype  and  RNA  level  determined,
nd  a liver  biopsy  should  be  considered  to  assess  the  degree
f  ﬁbrosis.  Validated,  non  invasive  methods,  as  hepatic  elas-
ography,  can  be  also  used  for  staging,  however,  in  the
eported  patient,  liver  biopsy  was  preferred  due  to  the
evel  of  increase  in  ALT,  which  has  been  shown  to  overes-
imate  liver  stiffness.  Biopsy  was  also  done  to  exclude  an
utoimmune  disorder  that  would  contraindicate  treatment.
reatment  should  be  individualized  and  considered  for  all
HC  patients.  HCV  infection  tends  to  induce  non-speciﬁc
utoimmune  reactions,  as  demonstrated  by  the  high  preva-
ence  of  various  non-organ-speciﬁc  autoantibodies,  usually
n  low  titers.12 Classic  HCV  infection  generally  is  not  charac-
erized  by  prominent  plasma  cell  inﬁltration  on  liver  biopsy, feature  that  is  often  prominent  in  AIH.  In  addition,  patients
ith  AIH  may  have  marked  elevations  in  serum  IgG,  a  fea-
ure  that  is  unusual  in  patients  with  HCV.13 The  current
uidelines  recommend  that  the  autoimmune  proﬁle  namely
tient
C
f
t
R
o
s
i
C
T
R
1
1
1
1
1
1
C. Isr Med Assoc J. 2009;11:760--1.The  Clinical  Signiﬁcance  of  Autoantibodies  in  Hepatitis  C  Pa
ANA  should  be  assessed  in  chronic  HCV  patients  before  the
treatment  decision  with  IFN  and  RBV  and  consider  the  pres-
ence  of  active  autoimmune  disorders  as  a  contraindication
for  treatment.  In  our  case,  serum  IgG  was  only  mildly  ele-
vated  and  hepatic  histology  did  not  show  a  prominent  plasma
cell  inﬁltration.  Even  though  current  guidelines  recommend
the  association  of  conventional  therapy  with  a  NS3  protease
inhibitor  agent  in  genotype  1,  there  are  no  recommendations
in  patients  with  possible  characteristics  of  autoimmunity,
but  it  could  be  expected  that  a  shorter  duration  of  IFN-
would  be  beneﬁcial.
Autoimmunity  in  HCV  infection  is  not  limited  to  autoan-
tibody  seropositivity,  but  embraces  the  full  spectrum  of
autoimmune  disorders.14 In  previous  reports  of  new  onset
or  exacerbation  of  psoriasis  after  interferon  therapy,  it  usu-
ally  occurred  4  weeks  after  the  initiation  of  treatment  and
cessation  of  medication  was  often  needed.  In  most  reported
cases  of  IFN- induced  new  onset  or  exacerbation  of  plaque-
type  psoriasis,  cessation  of  IFN- therapy  has  often  been
suggested,15 once  dose  reductions  of  IFN- do  not  seem  to
help  prevent  such  occurrences.16 Phototherapy  is  generally
considered  in  these  patients,  however,  there  have  been  sev-
eral  reports  of  liver  injury  after  PUVA  therapy.  MTX  is  not
recommended  for  the  treatment  of  psoriasis  in  patients  with
HCV  due  to  an  increased  risk  for  hepatotoxicity.  In  our  case,
the  patient  manifested  psoriatic  arthritis  at  week  22;  even
though  RVR  was  achieved,  abbreviated  treatment  (24  weeks)
could  not  be  considered  once  he  had  high  baseline  HCV-
RNA.4 Considering  that,  we  chose  to  maintain  treatment
with  a  reduced  dosage  of  peg-IFN  (135  mcg/weekly),  in  an
attempt  to  reduce  the  immunomodulatory  effects  exerted
by  IFN- that  may  further  facilitate  this  autoimmune  phe-
nomenon,  even  though  there  are  no  current  recommenda-
tions.  MTX  was  initiated,  together  with  Rheumatology,  and
was  well  tolerated  only  with  a  transaminases  ﬂare  8  weeks
after,  that  improved  after  MTX  dose  reduction.  We  chose  to
repeat  the  immune  panel  by  the  time  of  the  transaminases
elevation  due  to  fear  of  an  auto-immunity  ﬂare  triggered  by
IFN-,  and  also  excluded  HCV  breakthrough  due  to  reduced
peg-IFN  dosage  and  immunosupression.
Psoriasis  is  a  rare  complication  of  IFN- treatment.  A  pre-
disposition  to  autoimmunity  associated  with  the  presence  of
baseline  autoantibodies  has  been  demonstrated  in  previous
studies.  We  report  a  case  that  tries  to  explore  the  difﬁculties
in  the  differential  diagnosis  between  HCV  and  AIH,  as  well
as  the  clinical  signiﬁcance  of  autoantibodies  in  the  develop-
ment  of  autoimmune  manifestations,  like  psoriasis.  Numer-
ous  phase  2  and  3  studies  are  underway  assessing  the  effec-
tiveness  and  cutaneous  side-effects  of  IFN-free  regimens  for
the  treatment  of  HCV  infection.  The  incidence  of  psoriasis
onset  and  worsening  with  IFN-free  regimens  is  not  yet  avail-
able,  but  may  be  lower  than  the  incidence  with  IFN- treat-
ment.  Also,  IFN-free  regimens  will  probably  avoid  the  poten-
tial  of  aggravating  a  real  AIH  associated  with  CHC.  IFN-free
regimens  may  become  the  preferred  treatment  for  hepatitis
C  in  patients  with  psoriasis  and  other  autoimmune  diseases.
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